Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 and tretinoin are discussed for better absorption in hair loss treatment. The effectiveness of tretinoin with minoxidil is debated.

Treating hair loss with dermarolling and other treatments such as Minoxidil, Finasteride, and RU58841.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

Topical Minoxidil and RU58841 can make hair look brittle and thin, possibly due to the propylene glycol in their solutions. Some users experience side effects like heart palpitations with RU58841, while others have no issues.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The conversation discusses using RU58841, topical finasteride/minoxidil, MK677, and microneedling as treatments for hair loss. MK677 is mentioned as a growth hormone that improves hair health and recovery from microneedling.

The conversation discusses whether Breezula could be considered a cure for hair loss if it stops hair loss without side effects, acknowledging that it's not very effective for regrowing hair. Some believe a combination of hair transplants and topical treatments like Breezula could be effective, while others doubt its efficacy and the practicality of topicals as a cure.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

The user experienced almost no improvement in hair loss after 3 months using microneedling, RU58841, sulforaphane, finasteride, and dutasteride, especially after stopping minoxidil. They believe minoxidil is more effective than RU58841.

Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.

A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation humorously discusses hair loss treatments, specifically mentioning the use of finasteride, minoxidil, and RU58841. The tone is satirical, with the user playfully referring to themselves as a "finasteride D-rider."

The conversation humorously discusses using a dermaroller for hair growth, with a playful suggestion of using it on the wrist. It includes references to Minoxidil, finasteride, and RU58841 as treatments.

A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.